ES2093248T3 - Metodos y composiciones para la supresion de la transformacion mediada por el neu. - Google Patents

Metodos y composiciones para la supresion de la transformacion mediada por el neu.

Info

Publication number
ES2093248T3
ES2093248T3 ES92902782T ES92902782T ES2093248T3 ES 2093248 T3 ES2093248 T3 ES 2093248T3 ES 92902782 T ES92902782 T ES 92902782T ES 92902782 T ES92902782 T ES 92902782T ES 2093248 T3 ES2093248 T3 ES 2093248T3
Authority
ES
Spain
Prior art keywords
gene
neu
products
suppression
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92902782T
Other languages
English (en)
Spanish (es)
Inventor
Mien-Chie Hung
Di-Hua Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
University of Texas at Austin
Original Assignee
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System
Application granted granted Critical
Publication of ES2093248T3 publication Critical patent/ES2093248T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
ES92902782T 1990-12-04 1991-12-04 Metodos y composiciones para la supresion de la transformacion mediada por el neu. Expired - Lifetime ES2093248T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62146590A 1990-12-04 1990-12-04

Publications (1)

Publication Number Publication Date
ES2093248T3 true ES2093248T3 (es) 1996-12-16

Family

ID=24490270

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92902782T Expired - Lifetime ES2093248T3 (es) 1990-12-04 1991-12-04 Metodos y composiciones para la supresion de la transformacion mediada por el neu.

Country Status (11)

Country Link
US (1) US5651964A (cg-RX-API-DMAC7.html)
EP (1) EP0560932B1 (cg-RX-API-DMAC7.html)
JP (2) JPH06504671A (cg-RX-API-DMAC7.html)
AT (1) ATE142261T1 (cg-RX-API-DMAC7.html)
AU (1) AU651650B2 (cg-RX-API-DMAC7.html)
CA (1) CA2096723C (cg-RX-API-DMAC7.html)
DE (1) DE69121903T2 (cg-RX-API-DMAC7.html)
DK (1) DK0560932T3 (cg-RX-API-DMAC7.html)
ES (1) ES2093248T3 (cg-RX-API-DMAC7.html)
GR (1) GR3021805T3 (cg-RX-API-DMAC7.html)
WO (1) WO1992010573A1 (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641484A (en) * 1990-12-04 1997-06-24 Board Of Regents, The University Of Texas System Methods for the suppression of neu mediated tumors by adenoviral E1A and SV40 large T antigen
US5643567A (en) * 1990-12-04 1997-07-01 Board Of Regents, The University Of Texas System Methods for the suppression of neu mediated tumors by adenoviral E1A and SV40 large T antigen
US5516631A (en) * 1992-10-13 1996-05-14 La Jolla Cancer Research Foundation Method of inhibiting replication of hyperproliferative cells
AU5962694A (en) * 1992-12-31 1994-08-15 Exemplar Corporation Producing cells for transplantation to reduce host rejection and resulting cells
US5776743A (en) 1994-09-06 1998-07-07 La Jolla Cancer Research Foundation Method of sensitizing tumor cells with adenovirus E1A
US6326356B1 (en) * 1996-10-18 2001-12-04 Board Of Regents, The University Of Texas System Suppression of neu overexpression using a mini-E1A gene
US6008202A (en) * 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5763415A (en) * 1995-08-03 1998-06-09 John Hopkins University School Of Medicine Destruction of the epithelium of an exocrine gland in the prophylactic and therapeutic treatment of cancer
US6861506B1 (en) 1996-01-11 2005-03-01 Corixa Corporation Compositions and methods for the treatment and diagnosis of breast cancer
US6828431B1 (en) 1999-04-09 2004-12-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US7241876B2 (en) 1996-01-11 2007-07-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6656480B2 (en) 1996-01-11 2003-12-02 Corixa Corporation Compositions and methods for the treatment and diagnosis of breast cancer
CA2250222A1 (en) * 1996-03-20 1997-09-25 Mien-Chie Hung Sensitization of her-2/neu overexpressing cancer cells to chemotherapy
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
US7049410B2 (en) * 1999-05-14 2006-05-23 Majumdar Adhip P N Antibodies to a novel EGF-receptor related protein (ERRP)
US6399743B1 (en) 1999-05-14 2002-06-04 Dept. Of Veterans Affairs Isolation and characterization of a rat epidermal growth factor related protein
US9486429B2 (en) 1999-06-01 2016-11-08 Vanderbilt University Therapeutic methods employing nitric oxide precursors
US6346382B1 (en) 1999-06-01 2002-02-12 Vanderbilt University Human carbamyl phosphate synthetase I polymorphism and diagnostic methods related thereto
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
BR0013814A (pt) 1999-08-27 2002-04-23 Genentech Inc Métodos de tratamentos de um paciente humano suscetìvel a ou diagnosticado com uma doença com anticorpos anti-erbb2, artigos industrializados, métodos de tratamentos de câncer em pacientes humanos e usos do anticorpo anti-erbb2
US20040086903A1 (en) * 2000-12-29 2004-05-06 Jean-Jacques Lareyre Epididymal lipocalin gene and uses thereof
US20020169126A1 (en) * 2001-03-21 2002-11-14 Mien-Chie Hung Compositions and methods for inactivating the Akt oncogene and/or activating the p38 pro-apoptotic gene
US20050069918A1 (en) 2003-05-29 2005-03-31 Francois Claret JAB1 as a prognostic marker and a therapeutic target for human cancer
US20100132058A1 (en) 2004-07-23 2010-05-27 Diatchenko Luda B Methods and materials for determining pain sensitivity and predicting and treating related disorders
PT2247297T (pt) * 2008-01-31 2019-04-24 Univ Vanderbilt Tratamento terapêutico para estados pulmonares
HUE045571T2 (hu) 2008-01-31 2020-01-28 Univ Vanderbilt Koronáriás és artériás aneurizmás szubarachnoideális vérzés kezelésére szolgáló eljárások és készítmények

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) * 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
ES2067755T3 (es) * 1989-06-22 1995-04-01 Vestar Inc Proceso de encapsulado.
ATE237694T1 (de) * 1991-08-20 2003-05-15 Us Gov Health & Human Serv Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
US5496731A (en) * 1993-03-25 1996-03-05 Xu; Hong-Ji Broad-spectrum tumor suppressor genes, gene products and methods for tumor suppressor gene therapy

Also Published As

Publication number Publication date
DE69121903D1 (de) 1996-10-10
CA2096723C (en) 2006-03-28
EP0560932A1 (en) 1993-09-22
AU651650B2 (en) 1994-07-28
ATE142261T1 (de) 1996-09-15
DK0560932T3 (cg-RX-API-DMAC7.html) 1997-02-17
CA2096723A1 (en) 1992-06-05
JP2002114707A (ja) 2002-04-16
JP3323491B2 (ja) 2002-09-09
WO1992010573A1 (en) 1992-06-25
JPH06504671A (ja) 1994-06-02
AU9146991A (en) 1992-07-08
GR3021805T3 (en) 1997-02-28
US5651964A (en) 1997-07-29
DE69121903T2 (de) 1997-04-10
EP0560932B1 (en) 1996-09-04

Similar Documents

Publication Publication Date Title
ES2093248T3 (es) Metodos y composiciones para la supresion de la transformacion mediada por el neu.
WO1995016051A3 (en) Methods and compositions for the suppression of neu mediated transformation
Zhu et al. Oncogenic transformation of human mammary epithelial cells by autocrine human growth hormone
Christl et al. Antagonistic effects of sulfide and butyrate on proliferation of colonic mucosa: a potential role for these agents in the pathogenesis of ulcerative colitis
Nishihira et al. Molecular and cellular features of esophageal cancer cells
Easty et al. Ten human carcinoma cell lines derived from squamous carcinomas of the head and neck
Scheppach et al. Role of short-chain fatty acids in the prevention of colorectal cancer
ATE302764T1 (de) Benzyliden-thiazolidindione und analoga und ihre verwendung zur behandlung von diabetes
EP3677266B1 (en) Exon 18 and/or exon 21 mutant egfr selective inhibitor
Timmons et al. Expression of galectin-7 during epithelial development coincides with the onset of stratification
Shamloo et al. Dysregulation of adenosine kinase isoforms in breast cancer
Theodorescu et al. Inhibition of human bladder cancer cell motility by genistein is dependent on epidermal growth factor receptor but not p21ras gene expression
Easty et al. Five human tumour cell lines derived from a primary squamous carcinoma of the tongue, two subsequent local recurrences and two nodal metastases
Schmidt et al. Gastrointestinal cancer studies in the human to nude mouse heterotransplant system
Blagosklonny Cell immortality and hallmarks of cancer
IL147123A0 (en) Compositions containing soluble forms of hla-g for treating inflammatory skin pathologies
Russo et al. Ape1/Ref-1 expression and cellular localization in human thyroid carcinoma cell lines
Wang et al. The in vitro effect of vitamin D3 analogue EB‐1089 on a human prostate cancer cell line (PC‐3)
Nishi et al. Stimulation of growth by both androgen and estrogen of the EMP-K1 transplantable tumor with androgen and estrogen receptors from human extramammary Paget's disease in nude mice
Nio et al. Immunohistochemical expression of receptor-tyrosine kinase c-kit protein and TGF-β1 in invasive ductal carcinoma of the pancreas
GB2004550A (en) Dibenzocycloocten-imines
Lupulescu Effects of prostaglandins on tumor transplantation
RU2000101293A (ru) Производные бензо(5,6)циклогепта(1,2-в)пиридина для ингибирования фарнезил-протеин-трансферазы
Frazier et al. Cell lines of the human and rodent exocrine pancreas
Marozzi et al. by Transfection of H-2Kb Gene

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 560932

Country of ref document: ES